vaccin
repres
one
best
advanc
scienc
medicin
help
peopl
around
world
elimin
prevent
spread
infecti
diseas
although
mani
human
vaccin
develop
use
infecti
diseas
still
threat
peopl
health
especi
epidem
outbreak
sar
outbreak
asia
case
death
occur
econom
impact
sar
exceed
us
billion
accord
world
health
organ
report
largest
ebola
outbreak
west
africa
case
report
occur
fatal
estim
guinea
liberia
sierra
leon
endur
us
billion
loss
econom
growth
result
ebola
viru
diseas
outbreak
base
experi
west
africa
ebola
epidem
outbreak
publish
priorit
list
pathogen
like
caus
outbreak
situat
includ
ebola
viru
lassa
viru
marburg
viru
mrsa
zika
viru
etc
epidem
infecti
diseas
vaccin
current
develop
point
common
goal
countri
provid
equit
access
highqual
safe
afford
vaccin
immun
servic
throughout
life
cours
vaccin
long
list
achiev
past
vaccin
tremend
benefici
protect
individu
commun
seriou
infecti
diseas
reduc
healthcar
cost
around
world
develop
countri
vaccin
readili
avail
infant
children
adult
european
region
children
receiv
least
basic
vaccin
infanc
china
overal
vaccin
rate
basic
vaccin
recommend
infant
children
exceed
accord
data
publish
chines
center
diseas
control
prevent
ccdc
usa
advisori
committe
immun
practic
acip
recommend
routin
vaccin
program
vaccin
approv
regulatori
agenc
us
fda
immun
schedul
publish
us
cdc
differ
age
group
includ
infant
children
adolesc
adult
exampl
immun
schedul
infant
birth
month
includ
vaccin
potenti
seriou
ill
us
cdc
data
nation
immun
surveychild
nischild
databas
show
vaccin
rate
higher
usa
nation
huge
progress
vaccin
made
last
year
children
worldwid
million
receiv
essenti
lifesav
vaccin
protect
infecti
diseas
includ
measl
diphtheria
tetanu
pertussi
hepat
b
polio
vaccin
rate
increas
shown
fig
number
case
measl
pertussi
decreas
significantli
accord
report
repres
dedic
hard
work
includ
public
health
worker
research
pharmaceut
industri
polici
maker
parent
commun
howev
still
gap
vaccin
program
mani
countri
million
children
born
eu
region
infant
receiv
complet
threedos
seri
diphtheria
pertussi
tetanu
vaccin
first
birthday
data
show
measl
case
european
region
recent
year
accord
preliminari
data
measl
increas
around
global
first
month
compar
time
last
year
sizabl
increas
region
world
reason
children
get
vaccin
divers
differ
region
world
major
reason
lack
access
vaccin
servic
subsaharan
africa
region
lowest
coverag
greatest
burden
case
million
children
world
still
get
adequ
coverag
basic
vaccin
indic
european
vaccin
action
plan
evap
evap
goal
guid
countri
european
region
toward
joint
vision
region
free
vaccineprevent
diseas
establish
six
goal
includ
sustain
poliofre
statu
elimin
measl
rubella
control
hepat
b
infect
meet
region
vaccin
coverag
target
administr
level
throughout
region
make
evidencebas
decis
introduct
new
vaccin
achiev
financi
sustain
nation
immun
program
vaccin
develop
involv
mani
stakehold
multipl
disciplin
includ
scienc
medicin
public
health
regulatori
agenc
manufactur
healthcar
profession
vaccin
safeti
profession
consum
mani
countri
govern
agenc
play
import
role
vaccin
innov
develop
commerci
exampl
usa
nation
institut
health
nih
conduct
support
basic
research
translat
research
clinic
evalu
identifi
new
vaccin
target
advanc
new
vaccin
candid
product
develop
pipelin
regulatori
agenc
us
fda
involv
vaccin
review
licens
regulatori
scienc
manufactur
inspect
postlicensur
safeti
monitor
us
center
diseas
control
prevent
cdc
identifi
control
prevent
infecti
diseas
surveil
detect
respons
vaccin
use
recommend
vaccin
purchas
servic
deliveri
health
commun
postmarket
vaccin
safeti
effect
monitor
vaccin
highli
regul
product
requir
extens
safeti
monitor
usa
vaccin
regul
fda
center
biolog
evalu
research
cber
offic
vaccin
research
review
ovrr
author
resid
section
us
public
health
servic
act
feder
food
drug
cosmet
act
cber
conduct
thorough
review
laboratori
manufactur
clinic
data
ensur
safeti
efficaci
puriti
potenc
vaccin
product
figur
illustr
typic
process
vaccin
develop
licensur
vaccin
develop
long
expens
process
high
financi
risk
may
take
year
us
billion
develop
new
innov
vaccin
fact
cost
data
develop
new
vaccin
usual
scarc
accord
dimitrio
gougla
averag
cost
success
develop
epidem
infecti
diseas
vaccin
preclin
phase
estim
us
million
exclud
cost
facil
substanti
invest
need
develop
vaccin
new
target
innov
key
futur
develop
new
vaccin
combat
infecti
diseas
although
cost
vaccin
develop
high
benefit
vaccin
also
signific
develop
licensur
pneumococc
conjug
vaccin
pcv
good
exampl
bacteria
pneumonia
lead
caus
pneumonia
mortal
global
account
death
caus
etiolog
combin
death
occur
countri
africa
asia
year
streptococcu
pneumonia
caus
approxim
case
mening
case
pneumonia
requir
hospit
six
million
case
otiti
media
annual
usa
pneumococc
conjug
vaccin
approv
year
use
usa
design
cover
seven
serotyp
account
invas
infect
children
younger
year
age
publish
posit
paper
recommend
countri
includ
pcv
part
routin
infant
immun
schedul
later
pneumococc
conjug
vaccin
wide
use
world
countri
put
nation
immun
program
follow
introduct
pneumococc
conjug
vaccin
usa
reduct
pneumococc
diseas
invas
pneumococc
diseas
decreas
case
per
peopl
case
per
accord
data
publish
us
cdc
current
two
approv
pcv
vaccin
usa
includ
develop
market
gsk
prevnar
develop
market
wyeth
pharmaceut
pfizer
vaccin
industri
achiev
tremend
success
develop
human
vaccin
current
use
vaccin
clinic
trial
ongo
vaccin
candid
infecti
diseas
target
howev
remain
target
mani
signific
challeng
develop
new
vaccin
target
remain
infecti
diseas
id
vaccin
target
includ
diseas
affect
larg
popul
respiratori
syndrom
viru
rsv
diseas
human
immunodefici
viru
hiv
malaria
etc
emerg
infecti
diseas
lassa
marburg
ebola
mer
zika
list
vaccin
pipelin
track
sheet
develop
new
vaccin
remain
target
face
signific
challeng
vaccin
polici
maker
industri
need
work
togeth
encourag
innov
collabor
support
continu
promot
innov
vaccin
research
develop
polici
maker
regulatori
agenc
recogn
evolv
develop
scienc
medicin
use
new
approach
vaccin
review
approv
fasttrack
approach
well
clinic
trial
design
demonstr
ebola
clinic
trial
africa
outbreak
vaccin
manufactur
complex
process
vaccin
take
long
time
manufactur
rang
typic
month
month
manufactur
process
product
time
usual
dedic
qualiti
control
test
vaccin
manufactur
process
sever
hundr
qualiti
control
test
may
requir
releas
batch
vaccin
product
abil
manufactur
commerci
scale
also
import
new
vaccin
commerci
complex
costli
process
licens
new
vaccin
base
upon
demonstr
safeti
effect
clinic
evalu
abil
manufactur
consist
manner
process
develop
valid
critic
path
toward
develop
safe
effect
vaccin
includ
follow
speedi
develop
new
technolog
welldesign
welloper
facil
improv
manufactur
method
scaleup
improv
analyt
evalu
tool
refer
standard
streamlin
preclin
clinic
evalu
improv
intern
cooper
effect
vaccin
review
releas
process
improv
product
safeti
monitor
program
earli
phase
vaccin
develop
manufactur
follow
inform
critic
address
product
safeti
aspect
sourc
biolog
seed
cell
bank
character
raw
materi
includ
biolog
deriv
materi
cell
cultur
media
etc
initi
scalabl
process
develop
initi
product
character
testingqualificationclear
impur
contamin
process
control
especi
safeti
product
eg
steril
viru
clearanc
applic
clinic
develop
stage
follow
chemic
manufactur
control
cmc
activ
import
gradual
phasedin
approach
usual
taken
vaccin
develop
manufactur
process
appli
current
good
manufactur
practic
cgmp
import
ensur
product
safeti
efficaci
consist
highli
recommend
cgmp
effect
manufactur
product
use
clinic
studiesstart
phase
one
follow
gener
approach
principl
broadli
applic
tailor
cgmp
applic
specif
product
process
facil
assess
potenti
risk
take
appropri
action
riskbas
approach
wide
rang
technolog
use
develop
success
vaccin
includ
live
attenu
bacteria
virus
eg
bcg
mmr
etc
inactiv
bacteria
virus
eg
wholecel
pertussi
ipv
etc
protein
eg
diphtheria
tetanu
toxoid
polysaccharid
pneumovax
conjug
polysaccharid
eg
meningococc
conjug
vaccin
viruslik
particl
vlp
recombin
protein
applic
mrna
adjuv
develop
applic
mani
vaccin
involv
pathogen
thu
special
requir
facil
equip
design
depend
biosafeti
level
manufactur
method
includ
tradit
eggbas
influenza
manufactur
newli
develop
cell
culturebas
bioreactor
manufactur
tradit
eggbas
process
use
million
egg
year
larg
number
manual
handl
manufactur
test
advanc
autom
step
greatli
enhanc
process
consist
reduc
potenti
contamin
human
intervent
ferment
process
often
use
stainless
steel
ferment
manufactur
mani
current
bacteri
vaccin
market
cell
culturebas
product
process
use
mani
viral
vaccin
product
investig
new
vaccin
candid
often
use
singleus
bioreactor
advantag
singleus
bioreactor
includ
faster
lower
cost
initi
instal
faster
develop
cycl
quicker
deliveri
clinic
trial
materi
disadvantag
includ
higher
cost
oper
dispos
bioreactor
potenti
issu
mechan
strength
joint
port
bioreactor
typic
vaccin
manufactur
product
releas
process
includ
follow
step
cultur
process
select
bacteri
strain
viru
seed
cell
grow
appropri
cultur
media
ferment
cell
cultur
gener
desir
antigen
inactiv
pathogen
cultur
usual
inactiv
use
chemic
agent
eg
formalin
heat
eg
c
harvest
remov
cell
cell
debri
product
stream
antigen
separ
cell
filtrat
andor
centrifug
purif
impur
remov
harvest
purif
method
ultrafiltr
chromatographi
etc
antigen
also
concentr
purif
process
detoxif
toxin
pathogen
suppress
immunogen
maintain
product
bulk
drug
substanc
desir
antigen
collect
store
control
temperatur
futur
use
formul
target
antigen
assembl
togeth
excipi
make
final
formul
fill
process
final
formul
fill
autom
fill
machin
asept
condit
glass
vial
prefil
syring
packag
contain
outer
packag
fill
vial
syring
packag
secondari
contain
futur
storag
ship
qc
test
qualiti
control
laboratori
conduct
qualiti
control
test
intermedi
final
product
qa
releas
qualiti
assur
confirm
product
manufactur
test
accord
approv
specif
procedur
releas
final
releas
clinic
trial
clinic
trial
conduct
eu
region
qualifi
person
qp
releas
final
product
batch
clinic
trial
usag
final
releas
distribut
commerci
vaccin
product
mani
countri
requir
nation
regulatori
agenc
nra
releas
final
product
distribut
market
usa
european
union
china
product
ship
vaccin
product
current
store
ship
coldchain
manag
typic
c
product
ship
c
product
monitor
product
releas
market
product
safeti
monitor
seriou
advers
event
sae
track
report
back
manufactur
regulatori
agenc
accordingli
recent
year
new
trend
manufactur
vaccin
product
includ
often
vaccin
construct
deriv
recombin
technolog
shingrix
vaccin
adenovirusbas
ebola
vaccin
rvsvzebov
ebola
vaccin
recombin
technolog
use
new
recombin
pertussi
vaccin
develop
provid
higher
product
yield
less
impur
recent
year
singleus
technolog
use
often
mani
new
vaccin
develop
manufactur
process
advantag
use
singleus
technolog
vaccin
develop
manufactur
includ
minim
potenti
contamin
need
equip
clean
batch
need
less
requir
clean
valid
less
initi
capit
cost
fast
easi
instal
disadvantag
singleus
technolog
includ
follow
need
mechan
strength
avoid
compon
breakup
instal
test
probe
mix
may
good
stainless
steel
tank
potenti
leachabl
extract
materi
bag
scalabl
depend
bioreactor
design
suitabl
viral
product
bacteri
product
h
h
mao
chao
recent
advanc
dispos
manufactur
technolog
process
analyt
technolog
pat
made
continu
manufactur
possibl
applic
continu
process
antibodi
manufactur
report
number
confer
compani
wuxi
biolog
amgen
develop
purif
technolog
enabl
integr
continu
process
upstream
downstream
final
bulk
drug
substanc
manufactur
applic
continu
manufactur
vaccin
gain
attent
nonprofit
organ
bill
melinda
gate
foundat
report
privat
convers
applic
continu
manufactur
could
result
much
lower
cost
good
goal
make
vaccin
afford
everyon
world
greatli
improv
access
afford
vaccin
less
develop
nation
especi
gavi
global
allianc
vaccin
immunis
countri
raw
materi
media
use
vaccin
ferment
purif
process
mostli
anim
componentfre
avoid
potenti
bsets
risk
especi
final
product
one
big
challeng
manufactur
vaccin
product
materi
use
phase
clinic
trial
typic
manufactur
commercialscal
facil
mani
differ
technolog
platform
use
variou
vaccin
difficult
standard
facil
equip
uniqu
facil
equip
usual
necessari
vaccin
famili
vaccin
long
lead
time
build
new
commercialscal
manufactur
facil
typic
year
larg
capit
invest
often
requir
success
scaleup
requir
deep
understand
process
conduct
welldesign
experi
complet
process
scaleup
demonstr
assess
safeti
immunogen
two
differ
lot
diphtheria
tetanu
pertussi
hepat
b
haemophilu
influenza
type
b
vaccin
manufactur
use
smalland
largescal
manufactur
process
success
scaleup
complet
prove
clinic
trial
result
manufactur
biolog
product
includ
vaccin
often
consid
process
product
processproduct
tightli
link
clinic
experi
outcom
major
chang
manufactur
facil
manufactur
process
may
requir
regulatori
approv
even
conduct
addit
clinic
trial
thu
vaccin
manufactur
process
confirm
usual
chang
unless
strong
reason
make
major
chang
situat
make
process
improv
exist
vaccin
challeng
anoth
manufactur
challeng
lie
largescal
process
valid
expens
exercis
produc
fullscal
process
valid
lot
meet
regulatori
file
eg
linespecif
realtim
stabil
requir
fill
finish
usa
addit
vaccin
biolog
product
typic
low
fill
volum
high
throughput
million
ten
million
dose
annual
thu
challeng
run
product
fill
line
asept
condit
long
period
time
employe
train
andor
util
isol
technolog
import
moreov
live
viral
vaccin
flumist
measl
vaccin
live
bacteri
vaccin
bcg
vaccin
requir
dedic
fillandfinish
facil
avoid
potenti
contamin
addit
current
vaccin
typic
temperatur
sensit
thu
need
coldchain
storag
c
even
lower
temperatur
c
c
gener
signific
challeng
handl
inprocess
hold
final
product
storag
well
suppli
chain
manag
larg
cold
room
requir
manufactur
area
meet
coldchain
storag
requir
consist
electr
power
suppli
cold
storag
area
essenti
maintain
cold
temperatur
control
time
vaccin
produc
maintain
emerg
backup
power
suppli
event
power
outag
power
suppli
switch
backup
power
suppli
quickli
anoth
signific
challeng
unpredict
demand
season
vaccin
eg
flu
vaccin
vaccin
emerg
use
ebola
vaccin
vaccin
manufactur
need
advanc
procur
signific
lead
time
prepar
raw
materi
facil
equip
qualiti
control
human
resourc
product
vaccin
vaccin
unlik
pharmaceut
product
often
perceiv
well
character
due
complex
structur
properti
implic
phase
clinic
trial
need
conduct
use
clinic
trial
materi
made
largescal
manufactur
facil
ensur
consist
phase
clinic
materi
commerci
product
approach
conduct
clinic
bridg
studi
demonstr
equival
phase
clinic
trial
materi
commerci
materi
potenti
impact
requir
twofold
delay
final
facil
readi
requir
larg
capit
invest
facil
much
ahead
time
thu
import
perform
character
vaccin
product
earli
possibl
avoid
minim
costli
chang
later
phase
clinic
trial
stage
gener
vaccin
heterogen
structur
greater
character
vaccin
becom
preval
may
possibl
connect
structur
chang
vaccin
compon
chang
potenc
toxic
turn
may
provid
better
understand
certain
vaccin
function
interact
immun
system
inform
gain
area
undoubtedli
improv
effect
safeti
futur
vaccin
vaccin
divid
three
major
categori
live
vaccin
kill
attenu
vaccin
compon
subunit
vaccin
compon
vaccin
gener
easili
character
usual
consist
rel
small
number
immunogen
compon
live
killedattenu
vaccin
includ
complex
biolog
compon
attenu
kill
virus
intact
bacteria
multipl
bacteri
compon
advanc
proteom
make
character
even
difficult
vaccin
manag
character
vaccin
gener
involv
analysi
bacteri
strain
viru
seed
cell
bank
intermedi
bulk
drug
substanc
formul
final
bulk
finish
product
variou
physic
chemic
biolog
test
use
analys
differ
biolog
materi
purpos
character
test
ensur
product
qualiti
consist
genet
modifi
bacteri
strain
use
vaccin
manufactur
follow
test
need
perform
addit
gener
accept
character
test
bacteri
strain
genotyp
verif
pcr
verif
linear
plasmid
dna
gene
sequenc
verif
verif
flank
sequenc
tabl
exampl
qualiti
test
premast
seed
genet
modifi
bacteri
seed
recombin
pertussi
vaccin
develop
gmp
materi
manufactur
cellbas
process
use
viral
vaccin
develop
manufactur
character
viral
seed
cell
line
requir
addit
biolog
raw
materi
use
manufactur
process
also
character
clear
sourc
origin
potenti
risk
introduct
adventiti
agent
virus
process
product
stream
viral
product
us
fda
guidanc
character
qualif
cell
substrat
biolog
materi
use
product
viral
vaccin
infecti
diseas
indic
clearli
outlin
requir
character
cell
substrat
cell
bank
viral
seed
vaccin
intermedi
biolog
raw
materi
differ
stage
vaccin
develop
viral
subunit
vaccin
product
manufactur
import
factor
prevent
contamin
adventiti
materi
contamin
stage
process
import
demonstr
viral
clearanc
process
valid
howev
live
attenu
virus
whole
inactiv
viru
viruslik
particl
often
purifi
rigor
viral
subunit
vaccin
unlik
product
protein
product
possibl
introduc
valid
viral
inactiv
remov
step
mitig
risk
address
issu
requir
applic
gmp
principl
approach
develop
program
earli
stage
focus
histori
puriti
stabil
viral
seed
cell
bank
biolog
raw
materi
viral
vectorbas
vaccin
develop
common
viral
vector
rescu
synthes
plasmid
allow
traceabl
viral
vector
full
sequenc
perform
plasmid
result
viral
vector
studi
also
perform
demonstr
genet
stabil
vector
earli
stage
develop
manufactur
cell
line
essenti
origin
known
clear
histori
free
adventiti
agent
gener
cell
bank
process
develop
product
meet
gmp
requir
addit
import
maintain
segreg
process
throughout
develop
program
prevent
potenti
contamin
viral
stock
cell
bank
although
product
viral
vector
pose
number
technic
challeng
cell
cultur
recoveri
character
analyt
perspect
recombin
viral
vector
system
viru
essenti
use
deliveri
vehicl
manufactur
approach
independ
gene
carri
platform
process
develop
therefor
applic
platform
develop
product
vaccin
base
viral
vector
adenoviru
adenoassoci
viru
aav
lentiviru
cell
substrat
cell
line
intend
vaccin
manufactur
follow
character
test
document
need
provid
cell
substrat
properti
plasmid
sequenc
phenotyp
express
antigen
sourc
cell
line
includ
speci
origin
tissu
type
passag
histori
deriv
histori
viral
seed
intend
vaccin
manufactur
also
well
document
includ
sourc
biolog
start
materi
eg
plasmid
parent
virus
donor
screen
test
donor
medic
histori
manipul
viral
phenotyp
cold
adapt
develop
temperatur
sensit
attenu
virul
genet
manipul
reassort
recombin
nucleic
acid
sequenc
growth
characterist
product
cell
substrat
genet
marker
longterm
storag
condit
viabil
storag
genet
stabil
product
absenc
adventiti
agent
biolog
raw
materi
serum
biolog
sourc
raw
materi
also
control
prevent
adventiti
materi
contamin
continu
develop
safe
effect
innov
vaccin
around
world
call
new
technolog
vaccin
discoveri
area
also
new
technolog
character
vaccin
tradit
method
vaccin
character
reli
studi
physicalchem
properti
use
method
differenti
scan
colorimetri
dsc
thermogravimetr
analysi
tga
ph
variou
stress
condit
agit
freezethaw
etc
base
particul
format
method
quantit
protein
content
well
element
composit
method
capabl
determin
whether
end
product
consist
previou
batch
unabl
detect
small
chang
result
vaccin
reduc
even
lost
immunogen
chang
structur
vaccin
compon
physic
consequ
mani
result
reduc
vaccin
effect
techniqu
lack
sensit
come
detect
small
chang
structur
vaccin
compon
caus
fail
use
chang
caus
sever
side
reaction
even
small
quantiti
tga
dsc
use
analyz
denatur
point
vaccin
protein
nucleotid
test
gener
give
indirect
indic
chang
vaccin
time
stress
chang
protein
sequenc
modif
substanti
affect
denatur
kinet
techniqu
provid
way
correl
chang
actual
chang
structur
molecul
appear
ph
use
monitor
major
chang
composit
vaccin
rel
insensit
chang
physic
characterist
affect
vaccin
function
includ
particl
size
particl
size
distribut
clump
vaccin
antigen
degrad
function
vaccin
h
h
mao
chao
caus
unwant
side
effect
specif
test
quantit
protein
oligonucleotid
element
analysi
total
protein
content
bicinchonin
acid
bca
test
provid
vital
qualiti
control
data
troubleshoot
manufactur
problem
limit
valu
analyz
degrad
vaccin
sinc
element
composit
chang
degrad
repres
small
percentag
overal
element
composit
addit
protein
degrad
still
identifi
protein
total
protein
analysi
condit
use
assay
also
break
clump
protein
oligonucleotid
insensit
chang
caus
minor
structur
modif
molecul
besid
tradit
physic
chemic
test
vaccin
advanc
technolog
highresolut
mass
spectrometri
ms
nuclear
magnet
reson
nmr
spectroscopi
chromatographi
polymeras
chain
reaction
like
pharmaceut
product
develop
new
vaccin
includ
clinic
test
phase
wellcontrol
clinic
trial
data
collect
demonstr
vaccin
product
effect
clinic
endpoint
surrog
endpoint
reason
like
base
clinic
serolog
epidemiolog
therapeut
pathophysiolog
evid
provid
clinic
benefit
gener
clinic
trial
vaccin
includ
clinic
trial
phase
phase
phase
postapprov
phase
clinic
trial
test
initi
safeti
toler
candid
vaccin
phase
clinic
trial
test
safeti
immunogen
dose
rang
phase
clinic
trial
addit
safeti
data
immunogen
efficaci
prior
initi
phase
clinic
trial
recommend
vaccin
develop
continu
dialogu
regulatori
agenc
discuss
studi
detail
diseas
prevent
treatment
studi
site
subject
select
choic
control
group
trial
design
includ
endpoint
case
definit
diagnost
test
dose
select
dose
schedul
studi
durat
concomit
vaccin
medic
safeti
assess
ensur
meet
intend
goal
clinic
trial
product
licensur
vaccin
approv
licensur
regulatori
agenc
clinic
trial
data
show
product
safe
pure
potent
manufactur
facil
meet
standard
design
assur
vaccin
product
continu
safe
pure
effect
noninferior
administ
concomit
vaccin
regulatori
point
view
proof
effect
vaccin
would
consist
control
clinic
investig
adequ
wellcontrol
studi
unless
waiv
applic
vaccin
product
altern
method
adequ
substanti
effect
use
serolog
respons
data
previous
accept
correl
clinic
effect
exist
effect
may
proven
welldesign
singl
clinic
studi
case
prevent
vaccin
one
adequ
wellcontrol
clinic
trial
may
support
compel
anim
challengeprotect
model
human
serolog
data
passiv
antibodi
data
pathogenesi
inform
phase
vaccin
clinic
trial
usual
use
scale
manufactur
make
clinic
trial
materi
intend
commerci
manufactur
facil
requir
made
challeng
vaccin
develop
facil
need
readi
long
vaccin
approv
commerci
launch
unlik
therapeut
biolog
product
efficaci
phase
clinic
trial
vaccin
usual
need
demonstr
protect
healthi
peopl
particular
diseas
target
popul
thu
depend
diseas
burden
particular
candid
vaccin
phase
efficaci
clinic
trial
larg
enrol
sever
thousand
healthi
volunt
exampl
recent
approv
shingrix
vaccin
phase
clinic
trial
peopl
enrol
thu
phase
clinic
trial
prevent
vaccin
usual
lengthi
costli
estim
cost
phase
clinic
trial
prevent
vaccin
may
exceed
us
million
vaccin
immunogen
often
test
clinic
trial
exampl
clinic
trial
conduct
ebola
viru
diseas
vaccin
ebolaspecif
antibodi
respons
vaccinematch
zairemakona
glycoprotein
gp
assess
enzymelink
immunosorb
assay
elisa
method
antiadenoviru
neutral
antibodi
titer
detect
serum
neutral
assay
vaccin
gpspecif
igg
titer
h
h
mao
chao
import
data
immun
respons
vaccin
neutral
antibodi
detect
use
analyz
vector
immun
preexist
immun
influenc
vaccin
immunogen
specif
tcell
respons
quantifi
enzymelink
immunospot
elispot
assay
tumor
necrosi
peripher
blood
mononuclear
cell
phase
phase
ib
clinial
trial
conduct
china
anoth
phase
clinic
trial
conduct
sierra
leon
studi
result
demonstr
one
shot
intramuscular
inject
vaccin
could
elicit
strong
humor
cellular
immun
respons
three
clinic
trial
vaccin
produc
consider
gp
antibodi
respons
gpspecif
tcell
respons
healthi
african
particip
china
day
gp
antibodi
respons
peak
day
last
month
booster
sixth
month
gp
antibodi
respons
last
month
preexsit
immun
overcom
select
vaccin
dosag
anoth
exampl
shingrix
vaccin
shingrix
recombin
subunit
vaccin
design
restor
vzv
immun
individu
increas
risk
develop
shingl
due
age
immunodefici
vzv
ge
abund
envelop
glycoprotein
predominantli
express
surfac
virusinfect
cell
vzv
ge
protein
play
critic
role
viru
infect
sinc
involv
viru
entri
celltocel
spread
harbor
site
nand
olink
glycosyl
subunit
vaccin
elicit
stronger
virusspecif
tcell
respons
well
antibodi
bcell
respons
ge
compar
current
use
live
attenu
vaccin
zostavax
evid
indic
ge
protein
induc
neutral
antibodi
tcell
respons
ge
antigen
compon
shingrix
deriv
vzv
strain
isol
patient
sever
varicella
diseas
antigen
recombin
truncat
form
vzv
ge
recombin
protein
produc
chines
hamster
ovari
cho
cell
genet
modifi
express
vzv
ge
gene
mani
vaccin
clinic
trial
ongo
variou
vaccin
candid
publish
websit
either
clinicaltrialgov
clinicaltrialsregist
eu
combin
vaccin
consist
two
live
organ
inactiv
organ
purifi
antigen
either
combin
manufactur
singl
product
mix
immedi
administr
intend
prevent
multipl
diseas
prevent
one
diseas
caus
differ
strain
serotyp
organ
clinic
studi
design
demonstr
safeti
immunogen
efficaci
combin
vaccin
random
control
studi
efficaci
compon
demonstr
clinic
studi
ideal
clinic
trial
prospect
random
control
endpoint
use
evalu
efficaci
trial
rang
diseas
incid
wellestablish
correl
protect
vaccin
develop
clinic
trial
gener
take
stepwis
approach
start
adult
children
routin
vaccin
aim
pediatr
applic
clinic
trial
children
popul
group
normal
requir
meningococc
vaccin
pcv
vaccin
dtcp
vaccin
etc
howev
global
infecti
diseas
malaria
ebola
viru
diseas
children
suffer
even
greater
risk
immun
system
strong
adult
report
ebola
outbreak
democrat
republ
congo
one
third
report
case
children
adolesc
year
age
thu
import
includ
children
adolesc
vaccin
develop
program
global
infecti
diseas
unless
waiver
grant
regulatori
agenc
case
cours
diseas
effect
drug
suffici
similar
adult
pediatr
patient
regul
may
conclud
pediatr
effect
extrapol
adequ
wellcontrol
studi
adult
supplement
inform
obtain
pediatr
subject
immun
respons
studi
point
us
fda
guidanc
vaccin
clinic
trial
includ
pregnant
women
popul
group
reproduct
toxic
studi
need
complet
prior
includ
certain
global
infecti
diseas
tuberculosi
malaria
human
immunodefici
virusacquir
immunodefici
syndrom
aid
seriou
andor
lifethreaten
acceler
approv
may
grant
use
surrog
endpoint
clinic
endpoint
surviv
irrevers
morbid
vaccin
provid
meaning
clinic
benefit
prevent
spread
infecti
diseas
therapeut
benefit
patient
exist
treatment
special
vaccin
product
approv
may
grant
base
evid
effect
studi
anim
human
efficaci
studi
ethic
feasibl
case
approv
sponsor
must
conduct
postmarket
studi
field
studi
verifi
describ
biolog
product
clinic
benefit
assess
safeti
use
indic
circumst
studi
feasibl
ethic
one
exampl
appli
anim
rule
approv
anthrax
vaccin
us
fda
h
h
mao
chao
recent
year
sever
new
vaccin
approv
differ
countri
around
world
brief
descript
given
follow
section
shingl
caus
pain
rash
fluidfil
blister
sometim
caus
chronic
pain
shingl
viru
result
reactiv
varicella
zoster
viru
type
herp
zoster
viru
caus
chicken
pox
chicken
pox
initi
infect
shingl
reactiv
viru
year
later
shingl
may
develop
age
common
peopl
age
year
shingl
caus
substanti
pain
interfer
activ
daili
live
reduc
qualiti
life
estim
averag
overal
incid
shingl
per
person
year
increas
per
person
year
age
year
europ
accord
robert
w
johnson
studi
shingl
third
common
caus
chronic
neuropath
pain
usa
estim
approxim
case
yearli
vaccin
effect
way
reduc
incid
shingl
two
vaccin
shingl
approv
us
fda
merck
develop
zoster
vaccin
live
zvl
zostavax
use
sinc
peopl
year
older
second
vaccin
shingl
develop
gsk
compani
shingrix
recombin
zoster
vaccin
adjuv
indic
prevent
herp
zoster
shingl
adult
age
year
older
two
dose
second
dose
administ
month
first
dose
sinc
approv
shingrix
obtain
tremend
success
marketplac
usa
intern
sale
shingrix
exceed
us
billion
recommend
acip
prefer
shingl
vaccin
peopl
age
year
older
shingrix
suspens
inject
suppli
singledos
vial
lyophil
varicella
zoster
viru
glycoprotein
e
ge
antigen
compon
reconstitut
accompani
vial
adjuv
suspens
compon
reconstitut
singl
dose
shingrix
ml
ge
antigen
obtain
cultur
genet
engin
chines
hamster
ovari
cho
cell
carri
truncat
ge
gene
media
contain
amino
acid
albumin
antibiot
animalderiv
protein
ge
protein
purifi
sever
chromatograph
step
formul
excipi
fill
vial
lyophil
adjuv
suspens
compon
compos
monophosphoryl
lipid
mpl
salmonella
minnesota
saponin
purifi
plant
extract
quillaja
saponaria
molina
combin
liposom
formul
liposom
compos
dioleoyl
phosphatidylcholin
dopc
cholesterol
phosphatebuff
salin
solut
contain
disodium
phosphat
anhydr
potassium
dihydrogen
phosphat
sodium
chlorid
water
inject
reconstitut
ml
dose
formul
contain
recombin
ge
antigen
mpl
dose
also
contain
mg
sucros
stabil
mg
sodium
chlorid
mg
dopc
mg
potassium
dihydrogen
phosphat
mg
cholesterol
mg
sodium
dihydrogen
phosphat
dihydr
mg
disodium
phosphat
anhydr
mg
dipotassium
phosphat
mg
polysorb
reconstitut
shingrix
steril
opalesc
colorless
pale
brownish
liquid
shingrix
contain
preserv
dose
may
also
contain
residu
amount
host
cell
protein
dna
picogram
manufactur
process
shingrix
gone
multipl
clinic
trial
overal
adult
age
year
older
receiv
least
dose
shingrix
clinic
studi
safeti
shingrix
evalu
pool
data
placebocontrol
clinic
studi
studi
involv
subject
age
year
older
receiv
least
dose
shingrix
n
salin
placebo
n
administ
accord
schedul
studi
conduct
north
america
latin
america
europ
asia
australia
overal
popul
major
subject
white
follow
asian
black
racialethn
group
femal
safeti
profil
accept
phase
clinic
trial
demonstr
shingrix
shown
highli
efficaci
shingl
subject
year
age
subject
year
age
shingrix
current
signific
shortag
usa
around
world
suppli
issu
common
problem
mani
success
vaccin
product
well
effect
vaccin
develop
struggl
suppli
good
address
suppli
issu
mitig
ahead
time
gsk
announc
april
plan
expand
manufactur
facil
montana
capit
invest
us
million
ebola
virus
ebov
envelop
nonseg
negativestrand
rna
virus
belong
famili
filovirida
known
caus
lethal
hemorrhag
fever
human
nonhuman
primat
mortal
rate
ebola
viru
diseas
evd
formerli
known
ebola
hemorrhag
fever
sever
often
fatal
ill
human
ebov
transmit
among
human
close
contact
infect
blood
bodili
fluid
tissu
moreov
intent
releas
ebov
would
probabl
result
mucos
infect
smallparticl
aerosol
dispers
ebola
viru
first
discov
june
epidem
outbreak
africa
caus
ten
thousand
death
speci
ebola
virus
mainli
zair
sultan
type
outbreak
site
concentr
central
africa
countri
congo
sultan
uganda
south
africa
outbreak
west
africa
one
worst
ebola
epidem
august
director
gener
declar
outbreak
public
health
emerg
intern
concern
mani
method
use
develop
ebov
vaccin
vaccin
candid
test
nonhuman
primat
nhp
show
good
protect
vaccin
candid
includ
inactiv
vaccin
subunit
vaccin
nonrepl
viru
vector
vaccin
replic
viru
vector
vaccin
develop
protect
zair
ebolaviru
past
year
protect
mechan
vaccin
also
studi
result
show
antibodi
protect
essenti
recombin
ebola
viru
diseas
vaccin
success
develop
jointli
beij
institut
biotechnolog
cansino
biolog
inc
cansinobio
preclin
research
recombin
ebola
viru
diseas
vaccin
adenoviru
vector
initi
key
technolog
vaccin
prepar
evalu
base
ebola
gp
antigen
signific
gene
sequenc
variat
gp
antigen
zair
ebola
viru
strain
identifi
ebola
epidem
outbreak
west
africa
ensur
effect
vaccin
vaccin
design
accord
ebola
viru
genotyp
vaccin
candid
test
anim
model
confirm
immunogen
safeti
efficaci
challeng
studi
guinea
pig
nhp
cynomolgu
monkey
conduct
biosafeti
level
lab
public
health
agenc
canada
also
confirm
vaccin
candid
effect
protect
guinea
pig
nhp
ebola
viru
infect
cansinobio
start
develop
recombin
ebola
viru
diseas
vaccin
end
ebola
viru
diseas
outbreak
occur
west
africa
cell
line
use
product
licens
nation
research
council
nrc
canada
product
process
scale
success
key
materi
intermedi
final
product
includ
viru
seed
cell
bank
purifi
bulk
final
product
qc
test
releas
intern
entir
product
process
ebov
vaccin
anim
componentfre
process
largescal
product
adenovirus
well
character
optim
sever
vaccin
biolog
product
develop
use
vectorbas
technolog
platform
technolog
appli
vectorbas
product
demonstr
robust
scalabl
high
product
cansino
obtain
clinic
trial
permit
chines
food
drug
administr
nmpa
formerli
cfda
govern
sierra
leon
phase
phase
clinic
trial
conduct
china
sierra
leon
involv
total
subject
clinic
trial
result
indic
vaccin
safe
immunogen
immun
respons
level
human
compar
rvzvzebov
vaccin
develop
merck
clinic
trial
result
demonstr
well
toler
good
safeti
profil
test
subject
age
gmt
antigp
antibodi
peak
around
day
vaccin
regardless
dose
level
satisfactori
immun
respons
reach
dosag
vp
per
dose
preexist
immun
vector
overcom
proper
dose
select
vpdose
convers
rate
respons
fast
longlast
featur
could
offer
help
ebola
viru
diseas
outbreak
situat
octob
new
drug
registr
applic
nda
recombin
ebola
viru
vaccin
adenoviru
vector
approv
chines
food
drug
administr
cfda
manufactur
facil
includ
qc
test
center
fulli
valid
oper
cansinobio
current
approv
meningococc
acwi
conjug
vaccin
given
preteen
teen
age
year
booster
dose
year
protect
serotyp
c
anoth
meningococc
subgroup
b
vaccin
bexsero
trumenba
approv
adolesc
adult
popul
age
year
increas
risk
meningococc
b
diseas
bexsero
fdaapprov
vaccin
prevent
invas
diseas
caus
neisseria
meningitidi
serogroup
recommend
routin
vaccin
point
fact
mening
subgroup
b
infect
rare
usa
among
adolesc
young
adult
usa
case
report
annual
death
accord
cdc
outbreak
colleg
campus
case
death
bexsero
develop
novarti
market
gsk
compani
steril
suspens
three
recombin
protein
meningococc
outer
membran
vesicl
omv
recombin
protein
neisseri
adhesin
nada
neisseri
heparin
bind
antigen
nhba
factor
h
bind
protein
fhbp
individu
produc
escherichia
coli
purifi
omv
compon
produc
n
meningitidi
strain
express
outer
membran
protein
p
serosubtyp
antigen
adsorb
onto
aluminum
hydroxid
ml
dose
bexsero
formul
contain
recombin
protein
nada
nhba
fhbp
omv
mg
aluminum
hydroxid
mg
sodium
chlorid
mg
histidin
mg
sucros
ph
accord
product
insert
bexsero
suspens
intramuscular
inject
ml
singledos
prefil
syring
two
dose
given
least
month
apart
first
dose
anoth
approv
meningococc
group
b
vaccin
trumenba
develop
pfizer
initi
approv
trumenba
bival
meningococc
group
b
vaccin
contain
two
factor
h
bind
protein
fhbp
neisseria
meningitidi
n
meningitidi
serogroup
b
fhbp
conserv
outer
membran
h
h
mao
chao
lipoprotein
virul
factor
contribut
abil
bacteria
avoid
host
defens
trumenba
steril
suspens
two
recombin
lipid
factor
h
bind
protein
fhbp
variant
one
two
antigen
distinct
fhbp
subfamili
subfamili
subfamili
b
respect
protein
also
known
protein
protein
individu
produc
escherichia
coli
subsequ
purifi
ml
dose
trumenba
formul
contain
fhbp
variant
subtyp
total
protein
mg
polysorb
mg
mm
histidinebuff
salin
ph
accord
product
insert
trumenba
approv
use
individu
year
age
later
trumenba
vaccin
approv
three
dose
schedul
dose
administ
month
us
fda
addit
clinic
trial
result
also
demonstr
safe
coadminist
trumenba
vaccin
meningococc
group
c
polysaccharid
diphtheria
toxoid
conjug
vaccin
tetanu
toxoid
reduc
diphtheria
toxoid
acellular
pertussi
vaccin
adsorb
person
year
less
year
age
human
papillomaviru
hpv
sexual
transmit
viru
pass
genit
contact
skintoskin
contact
hpv
infect
caus
benign
malign
dysplast
anogenit
diseas
men
women
nearli
cervic
cancer
anal
cancer
caus
oncogen
hpv
type
gardasil
human
papillomaviru
recombin
vaccin
develop
merck
initi
approv
us
fda
prior
licensur
gardasil
merck
hpv
vaccin
gardasil
licens
gardasil
protect
diseas
caus
hpv
type
gardasil
includ
origin
four
hpv
type
gardasil
plu
addit
five
type
hpv
gardasil
indic
girl
women
age
year
prevent
cervic
vulvar
vagin
anal
cancer
caus
human
papillomaviru
hpv
type
genit
wart
condyloma
acuminata
caus
hpv
type
gardasil
also
indic
boy
men
age
year
prevent
anal
cancer
caus
hpv
type
genit
wart
condyloma
acuminata
caus
hpv
type
ml
dose
gardasil
contain
recombin
viruslik
particl
vlp
major
capsid
protein
hpv
type
adsorb
preform
aluminumcontain
adjuv
amorph
aluminum
hydroxyphosph
sulfat
aah
amount
hpv
type
protein
dose
follow
respect
avail
suspens
ml
singledos
vial
prefil
syring
intramuscular
administr
two
dose
month
month
three
dose
month
accord
product
insert
dengu
infect
caus
dengu
viru
includ
four
known
serotyp
dengu
viru
transmit
primarili
aed
aegypti
mosquito
well
member
aed
mosquito
famili
annual
estim
million
dengu
infect
occur
worldwid
approxim
million
associ
clinic
manifest
hospit
death
dengu
diseas
major
public
health
concern
countri
endem
asia
pacif
area
africa
latin
america
four
dengu
viru
serotyp
found
tropic
subtrop
region
includ
european
territori
dengu
endem
us
territori
american
samoa
guam
puerto
rico
us
virgin
island
dengu
tetraval
vaccin
develop
sanofi
pasteur
inc
approv
us
fda
may
dengvaxia
live
attenu
tetraval
chimer
viru
vaccin
contain
replic
gene
capsid
gene
attenu
yellow
fever
viru
prem
env
gene
four
serotyp
cyd
cyd
viru
purifi
vero
cell
indic
dengvaxia
vaccin
prevent
dengu
diseas
caus
dengu
viru
serotyp
individu
year
age
laboratoryconfirm
previou
dengu
infect
live
endem
area
previou
dengu
infect
assess
medic
record
previou
laboratoryconfirm
dengu
infect
current
serotest
safeti
effect
vaccin
determin
three
random
placebocontrol
studi
involv
approxim
individu
dengueendem
area
includ
puerto
rico
latin
america
asiapacif
region
vaccin
approxim
effect
prevent
symptomat
laboratoryconfirm
dengu
diseas
popul
year
age
previous
laboratoryconfirm
dengu
diseas
dengvaxia
alreadi
approv
countri
approv
european
union
dengvaxia
suppli
vial
lyophil
powder
contain
four
viru
compon
reconstitut
time
use
suppli
sodium
chlorid
diluent
nacl
reconstitut
ml
dose
dengvaxia
formul
contain
cyd
viru
compon
reconstitut
vaccin
administ
subcutan
three
dose
interv
day
month
month
accord
product
insert
enteroviru
one
major
caus
agent
outbreak
hand
foot
mouth
diseas
herpangina
asia
enteroviru
vaccin
develop
sinovac
biotech
china
use
vero
cell
subgenotyp
phase
studi
inactiv
vaccin
vero
cell
viru
complet
decemb
china
purpos
phase
clinic
studi
demonstr
safeti
immunogen
vaccin
prevent
hand
foot
mouth
diseas
caus
total
healthi
infant
volunt
age
month
old
data
phase
clinic
studi
suggest
inactiv
vaccin
clinic
accept
safeti
good
immunogen
healthi
chines
infant
phase
clinic
trial
conduct
china
healthi
infant
young
children
month
age
vaccin
efficaci
hand
foot
mouth
diseas
herpangina
vaccin
efficaci
hospit
hand
foot
mouth
diseas
neurolog
complic
immunogen
subgroup
children
immun
respons
elicit
twodos
vaccin
seri
particip
day
neutral
antibodi
titer
associ
protect
hand
foot
mouth
diseas
herpangina
vaccin
approv
chines
drug
administr
formerli
cfda
hepat
b
viru
infect
seriou
public
health
issu
million
person
infect
hepat
b
viru
hbv
worldwid
approxim
death
worldwid
report
mostli
due
chronic
hepat
b
result
endstag
liver
diseas
andor
hepatocellular
carcinoma
new
hbv
vaccin
recombin
adjuv
heplisavb
develop
dynavax
technolog
corpor
prevent
hepat
b
viru
infect
product
contain
recombin
hepat
b
surfac
antigen
adjuv
novel
cytosin
phosphoguanin
cpg
enrich
oligodeoxynucleotid
odn
phosphorothio
adjuv
indic
usag
immun
infect
caus
known
subtyp
hepat
b
viru
adult
year
age
older
product
heplisavb
iss
recombin
hepat
b
surfac
antigen
rhbsag
subtyp
adw
produc
yeast
cell
dosag
contain
two
ml
dose
administ
week
apart
heplisavb
suppli
singleus
vial
ml
volum
ml
dose
contain
hbsag
cpg
adjuv
mm
sodium
phosphat
mm
sodium
chlorid
ww
polysorb
ph
buffer
vaccin
contain
preserv
shelf
life
final
contain
product
month
ae
c
date
manufactur
accord
product
insert
heplisavb
vaccin
approv
us
fda
first
hepat
b
vaccin
approv
usa
last
year
although
rvsvebov
offici
approv
licens
yet
process
appli
licensur
us
fda
ema
europ
obtain
fasttrack
review
breakthrough
statu
complet
phase
clinic
trial
demonstr
safeti
efficaci
juli
clinic
result
ebola
suffit
ring
vaccin
phase
clusterrandom
trial
rvsvzebov
vaccin
guinea
obtain
publish
lancet
basi
interim
analysi
trial
show
vaccin
efficaci
vaccin
effect
cluster
level
includ
herd
immun
unvaccin
member
cluster
march
rvsvzebov
expand
access
compassion
use
trial
conduct
name
ring
vaccin
rvsvzebov
expand
access
respons
outbreak
ebola
viru
diseas
guinea
interim
result
publish
lancet
ring
vaccin
strategi
use
ebola
contact
total
individu
vaccin
four
ring
guinea
includ
individu
age
year
year
frontlin
worker
result
show
ring
vaccin
strategi
rapidli
safe
implement
scale
respons
ebola
viru
diseas
outbreak
rural
set
although
lot
progress
made
recent
combat
ebola
outbreak
congo
data
publish
gsell
camacho
regard
ring
vaccin
result
demonstr
efficaci
rvsv
vaccin
worrisom
survivor
ebola
viru
diseas
previous
guinea
outbreak
ebola
viru
day
caus
anoth
round
ebola
infect
among
peopl
contact
need
much
better
tool
monitor
situat
addit
despit
signific
progress
character
respons
vaccin
correl
protect
cop
ebola
viru
infect
establish
human
hold
true
even
rvsvzebov
advanc
ebola
vaccin
candid
one
demonstr
efficaci
human
far
chapter
publish
especi
challeng
emerg
outbreak
set
major
effort
would
requir
ensur
sampl
data
collect
clinic
trial
particip
emerg
outbreak
difficult
track
peopl
collect
sampl
test
integr
data
preclin
clinic
vaccin
studi
togeth
data
diseas
survivor
thu
essenti
identifi
ebola
vaccin
correl
h
h
mao
chao
protect
inform
gener
rvsvzebov
may
help
identifi
cop
ebola
vaccin
candid
although
may
also
differ
respiratori
syncyti
viru
rsv
import
caus
viral
lower
respiratori
tract
ill
infant
children
global
vaccin
current
approv
protect
vulner
popul
rsv
transmit
direct
indirect
contact
nasal
oral
secret
caus
repeat
infect
throughout
life
signific
diseas
pediatr
elderli
popul
pathogen
envelop
nonseg
singlestrand
negativesens
rna
pneumoviru
belong
famili
paramyxovirida
mani
develop
program
rsv
vaccin
ongo
preclin
stage
rsv
candid
vaccin
clinic
develop
rsv
candid
vaccin
develop
novavax
current
phase
clinic
trial
stage
rsv
vaccin
develop
setback
recent
novavax
phase
efficaci
trial
rsv
f
vaccin
matern
immun
reach
phase
primari
efficaci
endpoint
wwwnovavaxcom
access
apr
thirdtrimest
pregnant
women
enrol
larg
clinic
trial
clinic
trial
result
demonstr
effect
sever
rsv
case
far
approv
rsv
vaccin
market
yet
develop
work
continu
work
remain
done
estim
death
million
clinic
ill
due
malaria
major
subsaharan
africa
develop
malaria
vaccin
ongo
year
fact
malaria
caus
parasit
make
develop
effect
vaccin
malaria
difficult
develop
vaccin
bacteria
virus
vaccin
approv
market
prevent
malaria
present
time
clinic
trial
malaria
vaccin
ongo
vaccin
current
develop
includ
pneumococc
conjug
vaccin
hiv
vaccin
tb
booster
vaccin
zika
vaccin
lassa
vaccin
middl
east
respiratori
syndrom
coronaviru
merscov
vaccin
chikungunya
vaccin
nipah
viru
vaccin
develop
mrna
vaccin
achiev
signific
progress
recent
year
mani
challeng
provid
adequ
vaccin
around
world
firstli
vaccin
hesit
still
problem
mani
countri
includ
usa
uk
also
china
vaccin
hesit
includ
situat
vaccin
uptak
low
poor
avail
eg
lack
vaccin
lack
offer
access
vaccin
unaccept
traveldist
reach
immun
clinic
poor
vaccin
program
commun
etc
vaccin
hesit
reflect
concern
decis
vaccin
oneself
one
children
vaccin
hesit
refus
grow
trend
recent
year
hinder
elimin
erad
diseas
march
multipl
measl
outbreak
usa
part
new
york
citi
declar
emerg
due
measl
outbreak
although
concern
vaccin
safeti
link
vaccin
hesit
one
factor
may
relat
hesit
mani
factor
also
contribut
issu
vaccin
hesit
refus
factor
may
includ
compulsori
natur
vaccin
coincident
tempor
relationship
advers
health
outcom
unfamiliar
vaccineprevent
diseas
lack
trust
corpor
public
health
agenc
area
peopl
allow
particip
vaccin
program
religi
reason
area
peopl
limit
access
educ
know
much
benefit
vaccin
result
refus
vaccin
overal
vaccin
hesit
complex
rapidli
chang
global
problem
requir
ongo
monitor
countri
region
need
come
specif
strategi
address
issu
anoth
challeng
resurg
pertussi
diseas
despit
vaccin
dtp
infant
children
three
decad
occurr
pertussi
adolesc
adult
popul
recogn
although
adolesc
adult
signific
clinic
symptom
pertussi
bacteria
infect
transmit
diseas
infant
young
children
around
studi
european
region
ecdc
report
pertussi
found
young
adolesc
older
year
old
highest
infect
rate
young
infant
less
month
old
sever
infect
studi
result
demonstr
major
case
age
year
unvaccin
data
stress
need
refin
vaccin
strategi
final
aim
protect
infant
usa
mani
european
countri
immun
tdap
adolesc
adult
recommend
nation
immun
program
thu
recommend
tdap
immun
adolesc
adult
